Pulmocide
PrivateLast Round
Series C
Extension
Dec 6, 2022
Total Funding Raised
$205.3M
Company Overview
Pulmocide operates in Healthcare & Life Sciences and is based in London. Its latest recorded funding round was a Series C Extension round in December 2022.
Pulmocide is a biopharmaceutical company that specializes in the development of inhaled antifungal drugs aimed at treating acute and chronic respiratory diseases.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Pulmocide Comparables
Compare Pulmocide with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| F2G | 82% | |
| Pulmatrix, Inc. | 81% | |
| Matinas BioPharma Holdings, Inc. | 71% |
For institutional investors. Book with your work email.
Pulmocide Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series C Extension | Dec 6, 2022 | ||||
| Grant | Dec 6, 2021 | ||||
| Series C | May 27, 2021 | ||||
| Series B | Mar 20, 2017 | ||||
| Series A | Nov 20, 2013 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Pulmocide Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Pictet Group | Series C Extension |
| SV Health Investors | Series C, Series C Extension, Series B, Series A |
| IP Group | Series C, Series C Extension |
| F-Prime Capital | Series C, Series C Extension, Series B, Series A |
| Pictet Alternative Advisors | Series C Extension |
| Imperial Innovations | Series B |
| Imperial Innovations | Series B, Series A |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Dec 6, 2022
Raised $52M led by Pictet Group and Vivo Capital.
- Dec 6, 2021
$4M raised from the Cystic Fibrosis Foundation.
For institutional investors. Book with your work email.
Pulmocide Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Pulmocide's valuation, stock price, and market status.
Is Pulmocide a public or private company?
Pulmocide is a private company.
What is the current stock price of Pulmocide?
Pulmocide is a private company, so its shares have no public market price. Caplight tracks Pulmocide's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Pulmocide worth (valuation)?
Valuation information for Pulmocide is not publicly available.
Can I buy Pulmocide stock?
Pulmocide shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Pulmocide's last funding round?
Pulmocide's most recent funding round was Series C Extension on December 6, 2022.
Who are the main investors in Pulmocide?
Key investors in Pulmocide include Pictet Group, Pictet Alternative Advisors, SR One, Jeito Capital, Vivo Capital.
Will Pulmocide IPO soon?
No public IPO plans have been announced for Pulmocide.
How can I track Pulmocide secondary market activity?
Caplight tracks bids, offers, and trades in Pulmocide's shares on secondary markets.